Novel options for the treatment of castration-resistant prostate cancer

被引：12

作者：

Ohlmann, Carsten-H. ^{[1
]}

Merseburger, Axel S. ^{[2
]}

Suttmann, Henrik ^{[3
]}

Schilling, David ^{[4
]}

Trojan, Lutz ^{[5
]}

Kempkensteffen, Carsten ^{[6
]}

Corvin, Stefan ^{[7
]}

Mathers, Michael J. ^{[8
]}

Bastian, Patrick J. ^{[9
]}

机构：

[1] Univ Saarland, Dept Urol, D-66421 Homburg, Germany

[2] Hannover Med Sch, Dept Urol, D-3000 Hannover, Germany

[3] Urologikum Hamburg, Hamburg, Germany

[4] Univ Tubingen, Dept Urol, Tubingen, Germany

[5] Heidelberg Univ, Dept Urol, Med Fac Mannheim, D-6800 Mannheim, Germany

[6] Univ Med Berlin, Dept Urol, Charite, Berlin, Germany

[7] Fachzentrum Urol Eggenfelden, Eggenfelden, Germany

[8] PandaMED Remscheid, Remscheid, Germany

[9] Univ Munich, Urol Klin & Poliklin, Klinikum Univ Campus Grosshadern, Munich, Germany

来源：

WORLD JOURNAL OF UROLOGY | 2012年 / 30卷 / 04期

关键词：

Castration-resistant prostate cancer; Abiraterone; MDV3100; Zibotentan; Denosumab; Alpharadin; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; EVERY; 3; WEEKS; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; SIPULEUCEL-T; TUMOR PROGRESSION; CONTROLLED-TRIAL; CLINICAL-TRIAL; DOCETAXEL;

D O I：

10.1007/s00345-011-0796-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

引用

下载

页码：495 / 503

页数：9

共 50 条

[1] Novel options for the treatment of castration-resistant prostate cancer
Carsten-H. Ohlmann
Axel S. Merseburger
Henrik Suttmann
David Schilling
Lutz Trojan
Carsten Kempkensteffen
Stefan Corvin
Michael J. Mathers
Patrick J. Bastian
World Journal of Urology, 2012, 30 : 495 - 503
[2] New Treatment Options in Castration-Resistant Prostate Cancer
Armstrong, Andrew J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 690 - 693
[3] New treatment options for castration-resistant prostate cancer
Simondsen, Katherine
Kolesar, Jill
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 856 - 865
[4] Targeting treatment options for castration-resistant prostate cancer
Miller, Dannah R.
Ingersoll, Matthew A.
Teply, Benjamin A.
Lin, Ming-Fong
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2021, 9 (01): : 101 - 120
[5] Emerging treatment options for patients with castration-resistant prostate cancer
George, Daniel
Moul, Judd W.
PROSTATE, 2012, 72 (03): : 338 - 349
[6] Update on options for treatment of metastatic castration-resistant prostate cancer
Vishnu, Prakash
Tan, Winston W.
ONCOTARGETS AND THERAPY, 2010, 3 : 39 - 51
[7] Chemotherapy options in castration-resistant prostate cancer
Teply, Benjamin A.
Hauke, Ralph J.
INDIAN JOURNAL OF UROLOGY, 2016, 32 (04) : 262 - 270
[8] New treatment options for patients with metastatic castration-resistant prostate cancer
Higano, Celestia S.
CANCER TREATMENT REVIEWS, 2012, 38 (05) : 340 - 345
[9] Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
Heidegger, Isabel
Massoner, Petra
Eder, Iris E.
Pircher, Andreas
Pichler, Renate
Aigner, Friedrich
Bektic, Jasmin
Horninger, Wolfgang
Klocker, Helmut
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 138 : 248 - 256
[10] Novel strategies in the treatment of castration-resistant prostate cancer (Review)
Marech, Ilaria
Vacca, Angelo
Ranieri, Girolamo
Gnoni, Antonio
Dammacco, Franco
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (05) : 1313 - 1320

← 1 2 3 4 5 →